Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2–5.

Background: Dyslipidemia is a potentially modifiable risk factor in patients with chronic kidney disease (CKD). Information on the safety and efficacy of statins in pediatric CKD is limited. Methods: Patients with CKD stage 2–5 and aged 5–18 years with low-density lipoprotein cholesterol (LDL-C) > 1...

Full description

Bibliographic Details

Published in:	Pediatric Nephrology Vol. 38; no. 8; pp. 2763 - 2771
Main Authors:	Ramesh, Punitha Lakxmi, Khandelwal, Priyanka, Lakshmy, R., Sinha, Aditi, Bagga, Arvind, Hari, Pankaj
Format:	research tables/charts Journal Article
Published:	Springer Nature Aug2023
Online Access:	View this record in EBSCOhost